SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+11.87%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$807M
AUM Growth
+$807M
(+16%)
Cap. Flow
+$148M
Cap. Flow
% of AUM
18.35%
Top 10 Holdings %
Top 10 Hldgs %
42.29%
Holding
104
New
31
Increased
25
Reduced
14
Closed
27
Top Buys
| 1 |
Smith & Nephew
SNN
|
$27.1M |
| 2 |
SI-BONE Inc
SIBN
|
$20.9M |
| 3 |
Rigel Pharmaceuticals
RIGL
|
$16.9M |
| 4 |
Natera
NTRA
|
$16.3M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$15.9M |
Top Sells
| 1 |
CVRx
CVRX
|
$18.6M |
| 2 |
Vericel Corp
VCEL
|
$17.1M |
| 3 |
Eli Lilly
LLY
|
$14.3M |
| 4 |
HCA Healthcare
HCA
|
$8.29M |
| 5 |
Krystal Biotech
KRYS
|
$8.25M |
Sector Composition
| 1 | Healthcare | 97.15% |
| 2 | Consumer Staples | 1.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Neuropace
NPCE
$310M
| $11.3M | 1.17% |
2,428,714
+59,711
| +3% | +$277K |
|
|
27
Vericel Corp
VCEL
$1.69B
| $9.57M | 0.99% |
326,449
-582,548
| -64% | -$17.1M |
|
28
Lantheus
LNTH
$3.75B
| $9.39M | 0.97% |
+113,700
| New | +$9.39M |
|
29
Iovance Biotherapeutics
IOVA
$800M
| $8.86M | 0.92% |
+1,449,777
| New | +$8.86M |
|
|
BCYC
30
Bicycle Therapeutics
BCYC
$492M
| $8.76M | 0.91% |
411,800
+153,400
| +59% | +$3.26M |
|
|
INBX
31
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $8.27M | 0.86% |
438,002
-40,300
| -8% | -$760K |
|
32
Tandem Diabetes Care
TNDM
$834M
| $8.26M | 0.85% |
203,300
-109,200
| -35% | -$4.43M |
|
33
4D Molecular Therapeutics
FDMT
$302M
| $8.07M | 0.84% |
469,400
+214,700
| +84% | +$3.69M |
|
34
NovoCure
NVCR
$1.35B
| $7.82M | 0.81% |
+130,000
| New | +$7.82M |
|
35
Viking Therapeutics
VKTX
$3.02B
| $7.66M | 0.79% |
+460,000
| New | +$7.66M |
|
36
89bio
ETNB
$1.37B
| $7.52M | 0.78% |
494,000
+115,000
| +30% | +$1.75M |
|
37
C4 Therapeutics
CCCC
$182M
| $7.5M | 0.78% |
2,387,020
-53,823
| -2% | -$169K |
|
|
THER
38
DELISTED
THERATECHNOLOGIES INC COM
THER
| $7.36M | 0.76% |
9,090,511
+291,386
| +3% | +$236K |
|
|
39
Krystal Biotech
KRYS
$4.35B
| $6.82M | 0.71% |
85,179
-103,038
| -55% | -$8.25M |
|
40
Syndax Pharmaceuticals
SNDX
$1.39B
| $6.81M | 0.71% |
322,600
+102,600
| +47% | +$2.17M |
|
41
GeneDx Holdings
WGS
$3.65B
| $6.55M | 0.68% |
+17,940,000
| New | +$6.55M |
|
42
Alkermes
ALKS
$4.95B
| $6.48M | 0.67% |
+230,000
| New | +$6.48M |
|
|
NARI
43
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $6.26M | 0.65% |
101,450
-123,100
| -55% | -$7.6M |
|
44
Nuvalent
NUVL
$5.74B
| $6.18M | 0.64% |
+236,900
| New | +$6.18M |
|
|
KRTX
45
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $6.13M | 0.63% |
+33,740
| New | +$6.13M |
|
46
BridgeBio Pharma
BBIO
$9.91B
| $6.04M | 0.63% |
+364,000
| New | +$6.04M |
|
47
Mirum Pharmaceuticals
MIRM
$3.75B
| $5.81M | 0.6% |
+242,000
| New | +$5.81M |
|
48
Travere Therapeutics
TVTX
$1.75B
| $5.28M | 0.55% |
+234,600
| New | +$5.28M |
|
49
Keros Therapeutics
KROS
$640M
| $5.22M | 0.54% |
122,316
-110,800
| -48% | -$4.73M |
|
|
DICE
50
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $4.97M | 0.51% |
173,447
| – | – |
|